Earnings calls

Sudeep Pharma Limited concall ledger

Every earnings call for SUDEEPPHRM — management tone, guidance, KPIs and promise tracking, quarter by quarter.

SUDEEPPHRM · 3 transcripts · Healthcare · latest Q4 FY26

Sudeep Pharma Limited has 3 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.

Q4 FY26Published 22 May 2026Call held 22 May 2026

SUDEEPPHRM Q4 FY26 Earnings Call Transcript & Analysis

Revenue₹642.3 cr+28% YoYEBITDA₹221.9 cr+17% YoYEBITDA Margin34.6%PAT₹174.3 cr+26% YoY

Revenue (FY26) ₹642 cr (+28% YoY); EBITDA (FY26) ₹222 cr (+17% YoY); EBITDA Margin (FY26) 34.6%. FY26 Revenue grew by 27.9% to INR 642.3 crores.

Read full transcript & analysis

Q3 FY26Published 09 Feb 2026Call held 09 Feb 2026

SUDEEPPHRM Q3 FY26 Earnings Call Transcript & Analysis

EBITDA₹66.8 cr+60% YoYEBITDA Margin37.3%PAT₹47.7 cr+66% YoYTotal Income₹179.2 cr+52% YoY

EBITDA (Q3 FY26) ₹67 cr (+60% YoY); EBITDA Margin (Q3 FY26) 37.3%; PAT (Q3 FY26) ₹48 cr (+66% YoY). Total Income for Q3 FY26 grew 52% YoY to INR 179.2 crores.

Read full transcript & analysis

Q2 FY26Published 22 Dec 2025Call held 22 Dec 2025

SUDEEPPHRM Q2 FY26 Earnings Call Transcript & Analysis

EBITDA₹114.7 cr+21% YoYEBITDA Margin37.9%PAT₹78 cr+19% YoYTotal Income₹302.9 cr+31% YoY

EBITDA (H1 FY26) ₹115 cr (+21% YoY); EBITDA Margin (H1 FY26) 37.9%; PAT (H1 FY26) ₹78 cr (+19% YoY). H1 FY26 Total Income grew 31% YoY to INR 302.9 crores.

Read full transcript & analysis